PubMed · 2994235
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
B Ménégol-Couque, M Brard. 1985. [Gaviscon].. https://pubmed.ncbi.nlm.nih.gov/2994235/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The effect of polyelectrolyte cation specificity, charge density, and conformation on the interaction between furcelleran, kappa, iota, and lambda-carrageenan, respectively, and amitriptyline, an amphiphilic cationic drug molecule, was studied by means of a dialysis equilibrium technique. The carrageenans used in this study-furcelleran, kappa, iota, and lambda-carrageenan-had a charge density corresponding to 0.69, 0.92, 1.53, and 2.07 sulfate groups per disaccharide. In general, the binding isotherms followed the order Li(+) < Na(+) < N(CH3)(4)(+) < K(+) < or = Cs(+) approximately Rb(+), i.e., the binding isotherms were shifted to higher concentrations of free amphiphile according to the sequence indicated. This affinity sequence correlates well with that found for the dextran sulfate-amitriptyline system (A. Hugerth and L.-O. Sundelöf, Langmuir 2000, 16, 313-317). The factor determining the critical aggregation concentration in the presence of Na(+) compared to K(+) was found to be as follows: the flexibility (conformation) in the case of the lower charged carrageenans, i.e., furcelleran and kappa-carrageenan, charge density for iota-carrageenan, and in the lambda-carrageenan case the difference in the ROSO(3)(-)-alkali ion specificity.
Various amphiphilic derivatives of sodium alginate and hyaluronate were prepared by covalent fixation of long alkyl chains (dodecyl and octadecyl) with various ratios on the polysaccharide backbones via ester functions. In the semidilute regime, aqueous solutions of the resulting compounds exhibited the typical rheological properties of hydrophobically associating polymers: tremendous enhancement of zero shear rate Newtonian viscosity, steep shear-thinning behavior, and formation of physically cross-linked gel-like networks. The influence of the alkyl chain length, its content on the polysaccharide and of the polymer concentration in the solution was well identified. All obtained results are discussed with respect to the schedule of conditions related to materials, which could be used for cartilage repair, such as in synovial fluid viscosupplementation as well as in cartilage replacement. In particular, it is seen that HA-C(12)-5 (hyaluronate substituted with 5% of dodecyl chains) and HA-C(18)-1 (hyaluronate substituted with 1% of octadecyl chains) in a 0.15N NaCl solution at 8 g/L have rheological properties quite similar to those of healthy synovial fluid. On the other hand, the rheological parameters of solutions at 8 g/L in 0.15N NaCl of some of derivatives, such as, for example, AA-C(12)-8 (alginate substituted with 8% of dodecyl chains) or HA-C(18)-2, are well fitted for a use in cartilage repair.
The development and optimization of calcium alginate for potential use in endovascular occlusion was investigated by testing its in vitro and in vivo mechanical stability and biocompatibility. The compressive resistance, rheology, and polymer yield of reacted alginate, and the polymer viscosity of unreacted alginate, were assessed. Biocompatibility was tested by injecting calcium alginate into the kidney capsule of rats. The reactivity of alginates with various structures and levels of purity were compared visually and histologically. Results suggest that calcium alginate is a biocompatible and mechanically stable gel for endovascular applications. Purified alginates exhibited compressive strength of 22 kPa and above at 40% compression, with no significant loss in elasticity. Purified alginate strength was significantly higher than that of crude alginates (p < 0.08). Purified alginates also exhibited significantly lower tissue reaction than crude alginates (p < 0.05). Of the alginates tested, purified high guluronic acid alginates (PHG) exhibited optimal strength and polymer yield, increased biocompatibility, and decreased viscosity. Clinical embolization treatments may be improved with the development of stable and biocompatible polymers such as calcium alginate. Possible uses of improved endovascular polymers include treating arteriovenous malformations (AVMs), aneurysms, blood flow to tumors, and vascular hemorrhaging.